Results 281 to 289 of about 134,892 (289)

BCL2 Inhibitors: Insights into Resistance

2018
Over the last decade, improved understanding of the mechanisms and structures of proteins integral to apoptosis have enabled therapeutic targeting of BCL2 to become more specific, less toxic and ultimately more clinically effective. The first BCL2-selective inhibitor, venetoclax, is now approved for use in patients with relapsed and refractory chronic ...
Mary Ann Anderson, Andrew W. Roberts, John F. Seymour   +2 more
openaire   +2 more sources

The BCL2 code to dopaminergic development and Parkinson's disease

Trends in Molecular Medicine, 2013
Continuous, nonrandom cell death during development of the dopaminergic system is carefully orchestrated by locally secreted growth factors and the expression of transcription factors to ensure every neuron is carefully placed in its appropriate position and no 'miswiring' occurs.
van der Heide, L.P., Smidt, M.P.
openaire   +5 more sources

Poly (ADP‐ribose) polymerase‐1 binds to BCL2 major breakpoint region and regulates BCL2 expression

Journal of Cellular Biochemistry, 2010
AbstractBCL2, originally identified as a proto‐oncogene in B‐cell lymphoma, is a key regulator of apoptosis. Although it is more than 200 kb in length, at least 70% of the t(14;18) translocation in follicular lymphomas occurs at the BCL2 major breakpoint region (mbr), located in the 3′‐untranslated region (3'‐UTR). We have previously found that the mbr
Yujie Sun, Xiao Han, Feiran Gong, Nan Yang, Luan Sun, Dapeng Yang, Changyan Ma   +6 more
openaire   +3 more sources

BCL2

2008
The Bcl2 family of proteins belong to a peculiar class of proteins regulating apoptosis, cell cycle, differentiation, and autophagy; in oncology, the genes coding for these proteins could not be defined neither as dominant transforming oncogenes (such as myc), nor tumor suppressor genes (such as p53).
openaire   +2 more sources

BCL2-Hemmer verbessert Erstlinientherapie [PDF]

InFo Hämatologie + Onkologie, 2020
openaire   +1 more source

Inhibitors (BCL2 - MCL1 - CDK)

Clinical Lymphoma Myeloma and Leukemia, 2015
Jason E. Conage-Pough, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman, Shannon M. Matulis, Lawrence H. Boise, Vikas Gupta, K.G. Barnhart   +7 more
openaire   +2 more sources

P53 and Bcl2 in Cancer Larynx

Otolaryngology - Head and Neck Surgery, 2005
Moustafa S. Hammad, Mohammed A. Gomaa, Heba M. Tawfik, Abd elaziz H. Elsherif   +3 more
openaire   +2 more sources

BCL2 inhibition in double hit lymphoma

Leukemia & Lymphoma, 2015
Andrew W. Roberts, Mary Ann Anderson, David C.S. Huang   +2 more
openaire   +3 more sources

BCL2 inhibition: back to the future!

Blood
Martin J. S. Dyer, Harriet S. Walter
openaire   +2 more sources